Document is current
Any future updates will be listed below
-
Authors
Lauseker, Michael https://orcid.org/0000-0002-6662-7127
Sacha, Tomasz https://orcid.org/0000-0002-7207-6595
Klamova, Hana https://orcid.org/0009-0000-5020-7040
Yakoleva, Julia
Lomaia, Elza https://orcid.org/0000-0003-3290-7961
Milojkovic, Dragana
Fabisch, Christian
Nicolini, Franck E.
Olsson-Stromberg, Ulla
Zackova, Daniela
Lewandowski, Krzysztof
Ernst, Philipp https://orcid.org/0000-0001-5165-9874
Castagnetti, Fausto https://orcid.org/0000-0002-0602-2628
Hirschbühl, Klaus https://orcid.org/0000-0002-4847-7460
Zupan, Irena
Voskanyan, Astghik
Gołos, Aleksandra
Frietsch, Jochen J. https://orcid.org/0000-0002-1476-8059
Gil, Justyna
Faber, Edgar https://orcid.org/0000-0002-3259-7791
Krause, Stefan W. https://orcid.org/0000-0002-5259-4651
Parry, Anne
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
Heibl, Sonja
Franke, Georg-Nikolaus https://orcid.org/0000-0001-8239-002X
Casado, Luis Felipe
Paczkowska, Edyta https://orcid.org/0000-0001-7052-9741
Hebart, Holger https://orcid.org/0000-0003-4536-9955
Eder, Matthias
Anhut, Peter
Trautmann-Grill, Karolin https://orcid.org/0000-0002-9050-1049
Szczepanek, Elzbieta
Südhoff, Thomas
Patkowska, Elzbieta
Kiani, Alexander
Ernst, Thomas https://orcid.org/0000-0003-2147-489X
Apperley, Jane https://orcid.org/0000-0002-1710-1794
Mayer, Jiri
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Pfirrmann, Markus https://orcid.org/0000-0002-8948-0690
Brioli, Annamaria https://orcid.org/0000-0002-4072-7592
-
Funding
Funding for this research was provided by:
The project was supported by funding of the European LeukemiaNet (ELN).
Grant FF04 of the IZKF Jena University Hospital
- License Information
-
More Information
Article History
Received: 30 October 2025
Revised: 22 November 2025
Accepted: 27 January 2026
First Online: 19 February 2026
Competing interests
: TSa has participated in advisory boards and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, Angelini Pharma, GSK, and AOP Orphan. DZ has served as a member of advisory boards for Novartis, Zentiva, Ascentage, and Enliven; has served on speakers’ bureaus for Novartis and Angelini; has acted as a consultant for Novartis and Angelini; and has received travel grants from Novartis and Angelini. KL has participated in advisory boards and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, Angelini Pharma, GSK and AOP Orphan. PE has participated in advisory boards for Novartis and Pfizer, and has received research funding from Novartis. KH has participated in advisory boards from Pfizer, Novartis, Incyte, GSK, SERB and received honoraria and travel support from Jazz, Novartis, Gilead, Roche, Pfizer, Amgen, Astellas, Merck, and AbbVie. JF received honoraria from Novartis, Stemline, AbbVie, Medac, Therakos, JAZZ, Takeda and Janssen-Cilag. EF received honoraria from Angelini and Novartis and received study and travel support from Novartis. SH has participated in advisory boards and received honoraria and travel support from Novartis, BMS, Pfizer, Sanofi, AstraZeneca, Johnson & Johnson, GSK, Amgen, Gilead, and Roche. KTG has participated in advisory boards from Argenx, Amgen, Sanofi, Sobi and received honoraria and travel support from Grifols, Novartis, NovoNordisk, SOBI. JM received research support from Novartis. AK received research support from Novartis and participated in advisory boards and received honoraria from Novartis, Bristol Myers Squibb, and Pfizer. JFA has participated in advisory boards for Ascentage, Incyte, Novartis and Terns, has received honoraria from Incyte, Novartis and Paladin, and research support from Incyte and Pfizer. AB has participated in advisory boards from BMS, Janssen, GSK, Pfizer, AstraZeneca and Sanofi and received honoraria and travel support from BMS, Janssen, GSK, Sanofi, Amgen and AstraZeneca. All other authors declare no competing interests.
